A citation-based method for searching scientific literature

Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade, André Robidoux, Richard G Margolese, Joan James, Scott M Lippman, Carolyn D Runowicz, Patricia A Ganz, Steven E Reis, Worta McCaskill-Stevens, Leslie G Ford, V Craig Jordan, Norman Wolmark. JAMA 2006
Times Cited: 1074







List of co-cited articles
676 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
36

Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin,[...]. N Engl J Med 2011
551
27

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. Cancer Prev Res (Phila) 2010
386
25

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Bernard Fisher, Joseph P Costantino, D Lawrence Wickerham, Reena S Cecchini, Walter M Cronin, Andre Robidoux, Therese B Bevers, Maureen T Kavanah, James N Atkins, Richard G Margolese,[...]. J Natl Cancer Inst 2005
829
22

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Silvana Martino, Jane A Cauley, Elizabeth Barrett-Connor, Trevor J Powles, John Mershon, Damon Disch, Roberta J Secrest, Steven R Cummings. J Natl Cancer Inst 2004
431
20

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
M H Gail, L A Brinton, D P Byar, D K Corle, S B Green, C Schairer, J J Mulvihill. J Natl Cancer Inst 1989
20

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Jill Knox, Simon Cawthorn, Christobel Saunders, Nicola Roche, Robert E Mansel, Gunter von Minckwitz,[...]. Lancet 2014
337
20

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
S R Cummings, S Eckert, K A Krueger, D Grady, T J Powles, J A Cauley, L Norton, T Nickelsen, N H Bjarnason, M Morrow,[...]. JAMA 1999
18

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes. Lancet Oncol 2015
222
16

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
B Ettinger, D M Black, B H Mitlak, R K Knickerbocker, T Nickelsen, H K Genant, C Christiansen, P D Delmas, J R Zanchetta, J Stakkestad,[...]. JAMA 1999
16

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Elizabeth Barrett-Connor, Lori Mosca, Peter Collins, Mary Jane Geiger, Deborah Grady, Marcel Kornitzer, Michelle A McNabb, Nanette K Wenger. N Engl J Med 2006
658
16

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Trevor J Powles, Sue Ashley, Alwynne Tidy, Ian E Smith, Mitch Dowsett. J Natl Cancer Inst 2007
265
16

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
648
15

Validation studies for models projecting the risk of invasive and total breast cancer incidence.
J P Costantino, M H Gail, D Pee, S Anderson, C K Redmond, J Benichou, H S Wieand. J Natl Cancer Inst 1999
488
14

Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.
S G Smith, I Sestak, A Forster, A Partridge, L Side, M S Wolf, R Horne, J Wardle, J Cuzick. Ann Oncol 2016
125
14

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
J Cuzick, J Forbes, R Edwards, M Baum, S Cawthorn, A Coates, A Hamed, A Howell, T Powles. Lancet 2002
518
12

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Umberto Veronesi, Patrick Maisonneuve, Nicole Rotmensz, Bernardo Bonanni, Peter Boyle, Giuseppe Viale, Alberto Costa, Virgilio Sacchini, Roberto Travaglini, Giuseppe D'Aiuto,[...]. J Natl Cancer Inst 2007
147
12

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
Kala Visvanathan, Patricia Hurley, Elissa Bantug, Powel Brown, Nananda F Col, Jack Cuzick, Nancy E Davidson, Andrea Decensi, Carol Fabian, Leslie Ford,[...]. J Clin Oncol 2013
198
11

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Jack Cuzick, John F Forbes, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell. J Natl Cancer Inst 2007
354
11


Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
Jack Cuzick, Ivana Sestak, Bernardo Bonanni, Joseph P Costantino, Steve Cummings, Andrea DeCensi, Mitch Dowsett, John F Forbes, Leslie Ford, Andrea Z LaCroix,[...]. Lancet 2013
256
10

Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model.
Jeffrey A Tice, Steven R Cummings, Rebecca Smith-Bindman, Laura Ichikawa, William E Barlow, Karla Kerlikowske. Ann Intern Med 2008
330
10



Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
Jacques E Rossouw, Garnet L Anderson, Ross L Prentice, Andrea Z LaCroix, Charles Kooperberg, Marcia L Stefanick, Rebecca D Jackson, Shirley A A Beresford, Barbara V Howard, Karen C Johnson,[...]. JAMA 2002
10

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
Garnet L Anderson, Marian Limacher, Annlouise R Assaf, Tamsen Bassford, Shirley A A Beresford, Henry Black, Denise Bonds, Robert Brunner, Robert Brzyski, Bette Caan,[...]. JAMA 2004
9

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Andrew N Freedman, Binbing Yu, Mitchell H Gail, Joseph P Costantino, Barry I Graubard, Victor G Vogel, Garnet L Anderson, Worta McCaskill-Stevens. J Clin Oncol 2011
123
9


Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.
B Rockhill, D Spiegelman, C Byrne, D J Hunter, G A Colditz. J Natl Cancer Inst 2001
414
8

Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women.
Rayna K Matsuno, Joseph P Costantino, Regina G Ziegler, Garnet L Anderson, Huilin Li, David Pee, Mitchell H Gail. J Natl Cancer Inst 2011
90
8

Projecting individualized absolute invasive breast cancer risk in African American women.
Mitchell H Gail, Joseph P Costantino, David Pee, Melissa Bondy, Lisa Newman, Mano Selvan, Garnet L Anderson, Kathleen E Malone, Polly A Marchbanks, Worta McCaskill-Stevens,[...]. J Natl Cancer Inst 2007
185
8

Use of the Gail model and breast cancer preventive therapy among three primary care specialties.
Jennifer Corbelli, Sonya Borrero, Rachel Bonnema, Megan McNamara, Kevin Kraemer, Doris Rubio, Irina Karpov, Melissa McNeil. J Womens Health (Larchmt) 2014
30
26


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
8

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
Andrea DeCensi, Matteo Puntoni, Aliana Guerrieri-Gonzaga, Silvia Caviglia, Franca Avino, Laura Cortesi, Cristiana Taverniti, Maria Grazia Pacquola, Fabio Falcini, Marcella Gulisano,[...]. J Clin Oncol 2019
50
16

Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
Douglas K Owens, Karina W Davidson, Alex H Krist, Michael J Barry, Michael Cabana, Aaron B Caughey, Chyke A Doubeni, John W Epling, Martha Kubik, C Seth Landefeld,[...]. JAMA 2019
40
20


Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
J A Cauley, L Norton, M E Lippman, S Eckert, K A Krueger, D W Purdie, J Farrerons, A Karasik, D Mellstrom, K W Ng,[...]. Breast Cancer Res Treat 2001
473
7

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
Stuart L Silverman, Claus Christiansen, Harry K Genant, Slobodan Vukicevic, José R Zanchetta, Tobie J de Villiers, Ginger D Constantine, Arkadi A Chines. J Bone Miner Res 2008
302
7

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.
R R Love, R B Mazess, H S Barden, S Epstein, P A Newcomb, V C Jordan, P P Carbone, D L DeMets. N Engl J Med 1992
877
7

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
Andrea Z LaCroix, Trevor Powles, C Kent Osborne, Kevin Wolter, John R Thompson, David D Thompson, D Craig Allred, Róisín Armstrong, Steve R Cummings, Richard Eastell,[...]. J Natl Cancer Inst 2010
84
8

Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers.
Susan A Sabatino, Ellen P McCarthy, Russell S Phillips, Risa B Burns. Cancer Detect Prev 2007
71
9

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
7

Factors affecting breast cancer risk reduction practices among California physicians.
Celia Patricia Kaplan, Jennifer S Haas, Eliseo J Pérez-Stable, Genevieve Des Jarlais, Steven E Gregorich. Prev Med 2005
68
10

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill,[...]. Lancet 2013
7

Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer.
Jeffrey A Tice, Diana L Miglioretti, Chin-Shang Li, Celine M Vachon, Charlotte C Gard, Karla Kerlikowske. J Clin Oncol 2015
100
7

Atypical hyperplasia of the breast--risk assessment and management options.
Lynn C Hartmann, Amy C Degnim, Richard J Santen, William D Dupont, Karthik Ghosh. N Engl J Med 2015
146
7


Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Simon Cawthorn, Robert E Mansel, Sibylle Loibl, Bernardo Bonanni, D Gareth Evans, Anthony Howell. Lancet 2020
35
20

Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme.
E Amir, D G Evans, A Shenton, F Lalloo, A Moran, C Boggis, M Wilson, A Howell. J Med Genet 2003
180
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.